« Back
Home /
Satralizumab

Satralizumab

Item no.	HY-P99112-1mg
Manufacturer	MedChem Express
CASRN	1535963-91-7
Amount	1 mg
Quantity options	100 mg 10 mg 1 ea 1 mg 5 mg
Category	Antibodies In Vivo Antibodies
Type	Biosimilars
Specific against	other
Purity	99.82
Dry ice	Yes
Citations	[1]Heydari AH, et al. Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development. Cardiovasc Drugs Ther. 2021 Nov 26. [2]Duchow A, et al. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag. 2021 Feb;11(1):49-59.
Smiles	[Satralizumab]
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Shipping condition	Dry ice
Available
Manufacturer - Type	Inhibitory Antibodies
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Interleukin Related
Shipping Temperature	Dry Ice
Storage Conditions	Store at -80°C for 2 years
Product Description	Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	H2O
Manufacturer - Pathway	Immunology/Inflammation
Isoform	IL-6
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P99112-1mg-safety-datasheet.pdf